Presepsin levels in neonatal cord blood are not influenced by maternal SARS-CoV-2 infection.
COVID-19
early-onset sepsis
infection
neonate
newborn
Journal
Clinical chemistry and laboratory medicine
ISSN: 1437-4331
Titre abrégé: Clin Chem Lab Med
Pays: Germany
ID NLM: 9806306
Informations de publication
Date de publication:
26 08 2022
26 08 2022
Historique:
received:
14
03
2022
accepted:
10
06
2022
pubmed:
25
6
2022
medline:
5
8
2022
entrez:
24
6
2022
Statut:
epublish
Résumé
Coronavirus disease (COVID-19) can present with various symptoms and can involve multiple organs. Women infected during pregnancy have a higher incidence of obstetrical complications and infants born to "positive" mothers may get the infection with different manifestations. Presepsin seems to be a promising sepsis biomarker in adults and neonates. The aim of this study was to assess if presepsin levels in neonatal cord blood could be influenced by maternal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. A total of 119 neonates born from women with a confirmed diagnosis of SARS-CoV-2 infection were enrolled and presepsin levels of cord blood samples were collected. All neonates were tested for SARS-CoV-2 infection at birth and after 48-72 h. The median presepsin value in umbilical cord blood samples collected after birth was 455 pg/mL. Presepsin levels were not influenced by maternal symptoms of COVID-19, weight for gestational age, or delivery mode, and did not significantly differ between infants with and without adverse neonatal outcomes. Infants hospitalized for more than 5 days had a significantly higher presepsin level at birth rather than those discharged up to 4 days of life. Three infants with positive nasopharyngeal swab at birth had higher Presepsin levels than two infants tested positive at 48 h. This is the first study reporting cord presepsin levels in term and preterm infants born to mothers with COVID-19, that appeared to be not influenced by maternal clinical presentation. However, further studies are needed to explain the mechanisms of P-SEP increase in neonates exposed to perinatal maternal SARS-CoV-2 infection or with an indeterminate/possible SARS-CoV-2 infection in the same neonates.
Identifiants
pubmed: 35748906
pii: cclm-2022-0238
doi: 10.1515/cclm-2022-0238
doi:
Substances chimiques
Lipopolysaccharide Receptors
0
Peptide Fragments
0
presepsin protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1486-1491Informations de copyright
© 2022 Walter de Gruyter GmbH, Berlin/Boston.
Références
Figliozzi, S, Masci, P, Ahmadi, N, Tondi, L, Koutli, E, Aimo, A, et al.. Predictors of adverse prognosis in Covid-19: a systematic review and meta-analysis. Eur J Clin Invest 2020;50:e13362. https://doi.org/10.1111/eci.13362.
Abu-Raya, B, Michalski, C, Sadarangani, M, Lavoie, PM. Maternal immunological adaptation during normal pregnancy. Front Immunol 2020;11:1–18. https://doi.org/10.3389/fimmu.2020.575197.
Cornish, EF, Filipovic, I, Åsenius, F, Williams, DJ, McDonnell, T. Innate immune responses to acute viral infection during pregnancy. Front Immunol 2020;11:572567. https://doi.org/10.3389/fimmu.2020.572567.
Ciapponi, A, Bardach, A, Comandé, D, Berrueta, M, Argento, FJ, Cairoli, FR, et al.. COVID-19 and pregnancy: an umbrella review of clinical presentation, vertical transmission, and maternal and perinatal outcomes. PLoS One 2021;16:1–27. https://doi.org/10.1371/journal.pone.0253974.
Buonsenso, D, Costa, S, Giordano, L, Priolo, F, Colonna, AT, Morini, S, et al.. Short- and mid-term multidisciplinary outcomes of neonates exposed to SARS-CoV-2 in utero or during the perinatal period: preliminary findings. Eur J Pediatr 2022;11:1–14. https://doi.org/10.1007/s00431-021-04319-1.
Auriti, C, De Rose, DU, Mondì, V, Stolfi, I, Tzialla, C. Neonatal SARS-CoV-2 infection: practical tips. Pathogens 2021;10:1–14. https://doi.org/10.3390/pathogens10050611.
Ponti, G, Maccaferri, M, Ruini, C, Tomasi, A, Ozben, T. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci 2020;57:389–99. https://doi.org/10.1080/10408363.2020.1770685.
Smilowitz, NR, Kunichoff, D, Garshick, M, Shah, B, Pillinger, M, Hochman, JS, et al.. C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J 2021;42:2270–9. https://doi.org/10.1093/eurheartj/ehaa1103.
Piccioni, A, Santoro, MC, de Cunzo, T, Tullo, G, Cicchinelli, S, Saviano, A, et al.. Presepsin as early marker of sepsis in emergency department: a narrative review. Medicina 2021;57:1–11. https://doi.org/10.3390/medicina57080770.
Carpio, R, Zapata, J, Spanuth, E, Hess, G. Utility of presepsin (sCD14-ST) as a diagnostic and prognostic marker of sepsis in the emergency department. Clin Chim Acta 2015;450:169–75. https://doi.org/10.1016/j.cca.2015.08.013.
Maddaloni, C, De Rose, DU, Santisi, A, Martini, L, Caoci, S, Bersani, I, et al.. The emerging role of presepsin (P-SEP) in the diagnosis of sepsis in the critically ill infant: a literature review. Int J Mol Sci 2021;22:12154. https://doi.org/10.3390/ijms222212154.
Iskandar, A, Arthamin, MZ, Indriana, K, Anshory, M, Hur, M, Di Somma, S, et al.. Comparison between presepsin and procalcitonin in early diagnosis of neonatal sepsis. J Matern Fetal Neonatal Med 2019;32:3903–8. https://doi.org/10.1080/14767058.2018.1475643.
Yang, HS, Hur, M, Yi, A, Kim, H, Lee, S, Kim, SN. Prognostic value of presepsin in adult patients with sepsis: systematic review and meta-analysis. PLoS One 2018;13:e0191486. https://doi.org/10.1371/journal.pone.0191486.
Zaninotto, M, Mion, MM, Cosma, C, Rinaldi, D, Plebani, M. Presepsin in risk stratification of SARS-CoV-2 patients. Clin Chim Acta 2021;507:161–3. https://doi.org/10.1016/j.cca.2020.04.020.
Fukada, A, Kitagawa, Y, Matsuoka, M, Sakai, J, Imai, K, Tarumoto, N, et al.. Presepsin as a predictive biomarker of severity in COVID-19: a case series. J Med Virol 2021;93:99–101. https://doi.org/10.1002/jmv.26164.
Park, M, Hur, M, Kim, H, Lee, CH, Lee, JH, Kim, HW, et al.. Prognostic utility of procalcitonin, presepsin, and the VACO index for predicting 30-day mortality in hospitalized COVID-19 patients. Ann Lab Med 2022;42:406–14. https://doi.org/10.3343/alm.2022.42.4.406.
Jopling, J, Henry, E, Wiedmeier, SE, Christensen, RD. Reference ranges for hematocrit and blood hemoglobin concentration during the neonatal period: data from a multihospital health care system. Pediatrics 2009;123:e333–7. https://doi.org/10.1542/peds.2008-2654.
Pugni, L, Pietrasanta, C, Milani, S, Vener, C, Ronchi, A, Falbo, M, et al.. Presepsin (soluble CD14 subtype): reference ranges of a new sepsis marker in term and preterm neonates. PLoS One 2015;10:1–11. https://doi.org/10.1371/journal.pone.0146020.
Living guidance for clinical management of COVID-19: Living guidance, 23 November 2021- World Health Organization (WHO). https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-2.
Bellos, I, Fitrou, G, Pergialiotis, V, Thomakos, N, Perrea, DN, Daskalakis, G. The diagnostic accuracy of presepsin in neonatal sepsis: a meta-analysis. Eur J Pediatr 2018;177:625–32. https://doi.org/10.1007/s00431-018-3114-1.
Parri, N, Trippella, G, Lisi, C, de Martino, M, Galli, L, Chiappini, E. Accuracy of presepsin in neonatal sepsis: systematic review and meta-analysis. Expert Rev Anti Infect Ther 2019;17:223–32. https://doi.org/10.1080/14787210.2019.1584037.
Chiesa, C, Natale, F, Pascone, R, Osborn, JF, Pacifico, L, Bonci, E, et al.. C reactive protein and procalcitonin: reference intervals for preterm and term neonates during the early neonatal period. Clin Chim Acta 2011;412:1053–9. https://doi.org/10.1016/j.cca.2011.02.020.
Hofer, N, Zacharias, E, Müller, W, Resch, B. An update on the use of C-reactive protein in early-Onset neonatal sepsis: current insights and new tasks. Neonatology 2012;102:25–36. https://doi.org/10.1159/000336629.
Boechat, JL, Chora, I, Morais, A, Delgado, L. The immune response to SARS-CoV-2 and COVID-19 immunopathology – current perspectives. Pulmonology 2021;27:423–37. https://doi.org/10.1016/j.pulmoe.2021.03.008.
Qin, C, Zhou, L, Hu, Z, Zhang, S, Yang, S, Tao, Y, et al.. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis 2020;71:762–8. https://doi.org/10.1093/cid/ciaa248.
Ragab, D, Salah Eldin, H, Taeimah, M, Khattab, R, Salem, R. The COVID-19 cytokine storm; what we know so far. Front Immunol 2020;11:1–4. https://doi.org/10.3389/fimmu.2020.01446.
Zhu, H, Wang, L, Fang, C, Peng, S, Zhang, L, Chang, G, et al.. Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia. Transl Pediatr 2020;9:51–60. https://doi.org/10.21037/tp.2020.02.06.